{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T21:45:24Z","timestamp":1768340724552,"version":"3.49.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ashjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Society of Hypertension"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.jash.2014.08.009","type":"journal-article","created":{"date-parts":[[2014,8,19]],"date-time":"2014-08-19T17:47:25Z","timestamp":1408470445000},"page":"791-799","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["Pre-existing arterial hypertension as a risk factor for early left ventricular systolic dysfunction following (R)-CHOP chemotherapy in patients with lymphoma"],"prefix":"10.1016","volume":"8","author":[{"given":"Sebastian","family":"Szmit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wojciech","family":"Jurczak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan Maciej","family":"Zaucha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Drozd-Soko\u0142owska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wojciech","family":"Spycha\u0142owicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Joks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"D\u0142ugosz-Danecka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Torbicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jash.2014.08.009_bib1","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1056\/NEJM200004133421502","article-title":"Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy","volume":"342","author":"Felker","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jash.2014.08.009_bib2","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/annonc\/mdf118","article-title":"Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review","volume":"13","author":"Kremer","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jash.2014.08.009_bib3","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1093\/annonc\/mdn728","article-title":"Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk","volume":"20","author":"Barrett-Lee","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jash.2014.08.009_bib4","doi-asserted-by":"crossref","first-page":"5212","DOI":"10.1016\/j.ijcard.2013.08.033","article-title":"Premature cardiovascular mortality in lymphoma patients treated with (R)-CHOP regimen - a national multicenter study","volume":"168","author":"Jurczak","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jash.2014.08.009_bib5","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/hon.827","article-title":"Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines","volume":"25","author":"Rigacci","year":"2007","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.jash.2014.08.009_bib6","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1365-2141.2011.08786.x","article-title":"Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high \u2018life threat\u2019 impact cardiopathy","volume":"154","author":"Corazzelli","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jash.2014.08.009_bib7","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/cncr.21354","article-title":"Age and comorbidity impact surgical therapy in older bladder carcinoma patients: a population-based study","volume":"104","author":"Prout","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.jash.2014.08.009_bib8","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1001\/jama.291.20.2441","article-title":"Prognostic importance of comorbidity in a hospital-based cancer registry","volume":"291","author":"Piccirillo","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jash.2014.08.009_bib9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.taap.2013.08.012","article-title":"Differential cardiotoxicity in response to chronic doxorubicin treatment in male spontaneous hypertension-heart failure (SHHF), spontaneously hypertensive (SHR), and Wistar Kyoto (WKY) rats","volume":"273","author":"Sharkey","year":"2013","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.jash.2014.08.009_bib10","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/toxsci\/kfp092","article-title":"Continuous electrocardiogram reveals differences in the short-term cardiotoxic response of Wistar-Kyoto and spontaneously hypertensive rats to doxorubicin","volume":"110","author":"Hazari","year":"2009","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.jash.2014.08.009_bib11","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1016\/j.ejca.2013.04.030","article-title":"Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis","volume":"49","author":"Kalam","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jash.2014.08.009_bib12","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1200\/JCO.2007.13.5467","article-title":"Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial","volume":"26","author":"Perez","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jash.2014.08.009_bib13","doi-asserted-by":"crossref","first-page":"7811","DOI":"10.1200\/JCO.2005.02.4091","volume":"23","author":"Tan-Chiu","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jash.2014.08.009_bib14","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1200\/JCO.2006.09.1611","article-title":"Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial","volume":"25","author":"Suter","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jash.2014.08.009_bib15","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cardfail.2011.10.015","article-title":"Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer","volume":"18","author":"Tarantini","year":"2012","journal-title":"J Card Fail"},{"key":"10.1016\/j.jash.2014.08.009_bib16","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1093\/annonc\/mdg070","article-title":"Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma","volume":"14","author":"Limat","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jash.2014.08.009_bib17","first-page":"174","article-title":"Cardiac function and cardiopulmonary performance in patients after treatment for non-Hodgkin's lymphoma","volume":"53","author":"Elbl","year":"2006","journal-title":"Neoplasma"},{"key":"10.1016\/j.jash.2014.08.009_bib18","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1200\/JCO.2004.06.033","article-title":"Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults","volume":"22","author":"Hequet","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jash.2014.08.009_bib19","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1200\/JCO.1998.16.6.2070","article-title":"Late effects in long-term survivors of high-grade non-Hodgkin's lymphomas","volume":"16","author":"Haddy","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jash.2014.08.009_bib20","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1182\/blood-2006-07-034405","article-title":"Late cardiotoxicity after treatment for Hodgkin lymphoma","volume":"109","author":"Aleman","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jash.2014.08.009_bib21","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1200\/JCO.2007.14.1242","article-title":"Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma","volume":"26","author":"Hershman","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jash.2014.08.009_bib22","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-08-3392","article-title":"Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma","volume":"107","author":"Moser","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jash.2014.08.009_bib23","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.2009.23.8527","article-title":"Aortic stiffness increases upon receipt of anthracycline chemotherapy","volume":"28","author":"Chaosuwannakit","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jash.2014.08.009_bib24","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jcmg.2012.11.017","article-title":"Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease","volume":"6","author":"Drafts","year":"2013","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jash.2014.08.009_bib25","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1161\/CIR.0b013e3182a88099","article-title":"Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association","volume":"128","author":"Lipshultz","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jash.2014.08.009_bib26","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1161\/CIRCULATIONAHA.105.576850","article-title":"NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity","volume":"112","author":"Wojnowski","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jash.2014.08.009_bib27","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","article-title":"Risk factors for doxorubicin-induced congestive heart failure","volume":"91","author":"Von Hoff","year":"1979","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jash.2014.08.009_bib28","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2165\/00044011-200525110-00005","article-title":"Cost effectiveness of cardioprotective strategies in patients with aggressive non-Hodgkin's lymphoma","volume":"25","author":"Limat","year":"2005","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.jash.2014.08.009_bib29","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1200\/JCO.2001.19.7.1926","article-title":"Congestive heart failure after treatment for Wilms' tumor: a report from the National Wilms' Tumor Study group","volume":"19","author":"Green","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jash.2014.08.009_bib30","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1378\/chest.78.6.880","article-title":"Late, late doxorubicin cardiotoxicity","volume":"78","author":"Gottlieb","year":"1980","journal-title":"Chest"},{"key":"10.1016\/j.jash.2014.08.009_bib31","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.jash.2014.08.009_bib32","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/jcpt.12124","article-title":"Incidence and risk-factors of CHOP\/R-CHOP-related cardiotoxicity in patients with aggressive non-Hodgkin's lymphoma","volume":"39","author":"Limat","year":"2014","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.jash.2014.08.009_bib33","doi-asserted-by":"crossref","first-page":"8597","DOI":"10.1200\/JCO.2005.02.5841","article-title":"Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study","volume":"23","author":"Doyle","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jash.2014.08.009_bib34","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJM199506293322602","article-title":"Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer","volume":"332","author":"Lipshultz","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jash.2014.08.009_bib35","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/mpo.2950210704","article-title":"Increased risk of cardiac dysfunction after anthracyclines in girls","volume":"21","author":"Silber","year":"1993","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.jash.2014.08.009_bib36","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1600-0609.2006.00687.x","article-title":"Cardiac effects within 3 months of BEAC high-dose therapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation","volume":"77","author":"Kuittinen","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jash.2014.08.009_bib37","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1136\/hrt.2007.123299","article-title":"Subacute cardiac toxicity following autologous haematopoietic stem cell transplantation in patients with normal cardiac function","volume":"94","author":"Chung","year":"2008","journal-title":"Heart"},{"key":"10.1016\/j.jash.2014.08.009_bib38","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1182\/blood-2010-01-263764","article-title":"A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart disease","volume":"116","author":"Myrehaug","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jash.2014.08.009_bib39","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1182\/blood-2010-06-291328","article-title":"Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation","volume":"117","author":"Galper","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jash.2014.08.009_bib40","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jacc.2012.09.035","article-title":"Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy","volume":"61","author":"Thavendiranathan","year":"2013","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal of the American Society of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933171114007165?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933171114007165?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T03:47:27Z","timestamp":1565754447000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933171114007165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":40,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S1933171114007165"],"URL":"https:\/\/doi.org\/10.1016\/j.jash.2014.08.009","relation":{},"ISSN":["1933-1711"],"issn-type":[{"value":"1933-1711","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pre-existing arterial hypertension as a risk factor for early left ventricular systolic dysfunction following (R)-CHOP chemotherapy in patients with lymphoma","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Society of Hypertension","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jash.2014.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 American Society of Hypertension. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}